SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (747)9/27/2007 12:28:47 PM
From: JibacoaRead Replies (1) | Respond to of 802
 
Looking back. (Partially O.T.)

Well,it has been more than 4 Yrs since Rodman & Renshaw started coverage of INGN with a target of $20 <g>

Message 19296080

I have been playing with INGN stock for some time,selling it on sudden spikes after news & buying when breaking from depressed bases that were formed after some negative articles on gene therapy or unjustified tirades like the one from A.F.

The cost of my present small position is negative if I take into account the previous gains trading the stock, but I am now thinking on taking a more substantial stake, in spite of the recent negative articles on gene therapy,since it seems the R/R is favorable at present levels.( I also like the nice short ratio.<g>)

bigcharts.marketwatch.com

Bernard